Results 31 to 40 of about 201 (100)

Clinical and immunological analysis of letermovir for preventing cytomegalovirus infection in children after hematopoietic stem cell transplantation

Frontiers in Immunology
ObjectiveThe present study aimed to analyze the efficacy and safety of letermovir for preventing cytomegalovirus (CMV) infection and its impact on immune reconstitution in children after allogeneic hematopoietic stem cell transplantation (allo-HSCT ...
Qing Liu, Bing Zhou, Na Zhang, Hong Li, Sijian Wang, Shumin Hou, Yilin Wang, Pan Fu, Tianqiao Zhong, Jingbo Shao, Kai Chen, Hui Jiang   +11 more
doaj   +1 more source

Letermovir Effectively Prevents Cytomegalovirus Infection in Patients with Aplastic Anemia After Hematopoietic Stem Cell Transplantation: A Real-World Retrospective Cohort Study

Infectious Diseases and Therapy
Introduction In this single-center retrospective cohort study, we investigated the efficacy of letermovir in preventing Cytomegalovirus (CMV) infection in patients with aplastic anemia (AA) who have undergone allogeneic hematopoietic stem cell ...
Yuling Zhang, Xiaowei Chen, Ming Zhou, Yuping Zhang, Cunte Chen, Ruiqing Zhou, Yumiao Li, Fangfang Yang, Shilin Xu, Caixia Wang, Wei Zhou, Tingfen Deng, Shiyi Pan, Wenjian Mo, Shunqing Wang   +14 more
doaj   +1 more source

Identification of a binding pocket of letermovir in the terminase subunit pUL56 of human cytomegalovirus

Scientific Reports
A key step in replication of human cytomegalovirus (HCMV) is the generation and packaging of unit-length genomes into preformed capsids. The enzymes involved in this process are viral terminases.
Lukas M. Kmetsch, Hans Tietze, Elke Bogner   +2 more
doaj   +1 more source

Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir

Infectious Disease Reports
Cytomegalovirus (CMV) infections may increase morbidity and mortality in immunocompromised patients. Until recently, standard antiviral drugs against CMV were limited to viral DNA polymerase inhibitors (val)ganciclovir, foscarnet and cidofovir with a ...
Jocelyne Piret, Guy Boivin
doaj   +1 more source

DNA Encapsidation and Capsid Assembly Are Underexploited Antiviral Targets for the Treatment of Herpesviruses

Frontiers in Microbiology, 2020
Although there are effective nucleoside analogs to treat HSV, VZV, and HCMV disease, herpesvirus infections continue to contribute to significant morbidity and mortality. Acyclovir is the drug of choice for HSV encephalopathy, yet there is an estimated 6–
Tara Keil, Dongmei Liu, Megan Lloyd, Wanda Coombs, Jennifer Moffat, Robert Visalli   +5 more
doaj   +1 more source

Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review

Infection and Drug Resistance, 2019
Guy El Helou,1,2 Raymund R Razonable1,21Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2William J von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN, USAAbstract ...
El Helou G, Razonable RR
doaj  

ID222 Análise de custo-efetividade e impacto orçamentário do letermovir como profilaxia da infecção e doença por citomegalovírus em pacientes adultos soropositivos (CMV R+) receptores de transplante de células-tronco hematopoiéticas alogênico, na perspectiva do Sistema Único de Saúde

Jornal de Assistência Farmacêutica e Farmacoeconomia
Introdução A população de pacientes submetidos ao transplante de células tronco hematopoiéticas (TCTH) é mais suscetível a infecções, devido ao estado imunocomprometido.
Álex Brunno do Nascimento Martins, Bárbara Rodrigues Alvernaz dos Santos, Eduardo Henrique Ferreira Bambirra, Francisco de Assis Acurcio, Luana Oliveira Prata, Juliana Alvares-Teodoro, Maiara Silva Araújo, Roberto Lúcio Muniz Júnior, Wallace Breno Barbosa, Augusto Afonso Guerra Júnior   +9 more
doaj   +1 more source

Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation

Blood Science
Letermovir is a specific inhibitor of cytomegalovirus (CMV) terminase complex. Several studies have reported that letermovir can effectively prevent CMV activation after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We aimed to identify
Wen-Wen Li, Yong-Mei Zhang, Meng-Zhu Shen, Xiao-Dong Mo   +3 more
doaj   +1 more source

Human cytomegalovirus control in allogeneic stem cell transplant recipients in the letermovir era – emerging humoral and cellular players

Haematologica
Allogeneic hematopoietic stem cell transplant (alloSCT) recipients frequently experience late-onset human cytomegalovirus (HCMV) reactivations following termination of letermovir prophylaxis.
Chris D. Lauruschkat, Hannah Görge, Kerstin Knies, Benedikt Weißbrich, Lars Dölken, Carolin Köchel, Nina Imhof, Magdalena Huber, Hartmut Hengel, Hermann Einsele, Sebastian Wurster, Sabrina Kraus   +11 more
doaj   +1 more source

Letermovir [PDF]

Reactions Weekly, 2020
openaire   +2 more sources